CClinicalTrials.gg
RecruitingNCT05224323AVALANCHEUpdated Dec 24, 2025

Avalanche Phenomenon During Airways Opening in Acute Respiratory Distress Syndrome

An observational study in Acute Respiratory Distress Syndrome, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Poitiers University Hospital · Observational

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Acute respiratory distress syndrome accounts for 23% of mechanically ventilated patients and is associated with high mortality rate. Although life-saving, mechanical ventilation may worsen lung injury through two main mechanisms: lung overdistension and atelectrauma. Indeed, the cyclic opening and closure of airways during tidal ventilation may cause lung and bronchial injuries as suggested by animal models and autopsy findings. Complete airways closure has recently been described in 40% of patients with acute respiratory distress syndrome, and setting positive end-expiratory pressure above the airway opening pressure may limit atelectrauma. However, animal and mathematical models suggest that above the airway opening pressure, more distal airways open unevenly according to their own opening pressure, resulting in an "avalanche"-like phenomenon during lung inflation. This phenomenon has never been described in humans. A better understanding of the opening of airways in acute respiratory distress syndrome may help to limit ventilation-induced lung injury and to improve outcomes.

02

Conditions studied

  • Acute Respiratory Distress Syndrome
03

In context

Respiratory Distress Syndrome

1,596 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.

This study's planned enrollment of 50 is below the median of 100 across 540 observational studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 310 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with moderate-to-severe acute respiratory distress syndrome will be included within the first 72 hours after meeting the Berlin definition criteria.

After ruling out exclusion criteria and obtaining informed consent from their relatives, patients will be included in the study.

Inclusion criteria

  • Age ≥ 18
  • Moderate-to-severe acute respiratory distress syndrome within the first 72 hours after meeting the Berlin definition criteria:
  • Within 1 week of a known clinical insult or new or worsening respiratory symptoms;
  • Bilateral opacities (not fully explained by effusions, lobar/lung collapse, or nodules);
  • Respiratory failure not fully explained by cardiac failure or fluid overload;
  • PaO2/FiO2 ≤ 200 mmHg with positive end-expiratory pressure ≥ 5 cmH2O.
  • Absence of spontaneous breathing efforts
  • Consent to participate to the study from the patient and/or its surrogate

Exclusion criteria

Exclusion Criteria:

  • Pneumothorax
  • Broncho-pleural fistula
  • Tracheostomy
  • Hemodynamic instability
  • Severe hypoxemia
  • Suspected of proven intracranial hypertension
  • Chronic obstructive lung disease
  • Pacemaker or defibrillator
  • Decision to withhold of withdraw life-sustaining measures
  • Under protection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes

Interventions

  • OtherAirway pressure, flow, esophageal pressure, ventilation distribution

    After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.

06

What researchers measure

Primary outcomes

  1. To assess the prevalence of "avalanche" phenomenon during low-flow lung inflation.

    The distribution of pressure drops on low-flow inflation pressure-volume curves will be described and plotted on a log-log scale graph. "Avalanche" phenomenon will be defined if this distribution follows power law (i.e. is linear on a log-log scale) with a R2 ≥ 0.80. The prevalence of "avalanche" phenomenon will be described as frequency and 95% confidence interval.

    Time frame: At inclusion

Secondary outcomes

  1. To compare characteristics of patients and their outcomes according to the existence of "avalanche" phenomenon during low-flow lung inflation.

    Continuous variables will be summarized as mean ± standard deviation or median \[25th-75th percentile\] according to their distribution and compared by means of the Mann-Whitney or the Student's t test. Categorical variables will be summarized as frequency (percentage) and 95% confidence interval, and compared by means of Fisher or Chi2 test.

    Time frame: Day 28

  2. To assess the existence of an inflection point on the low-flow deflation pressure-volume curve.

    The slope of the low-flow deflation pressure-volume curve will be computed by means of linear regression and summarized as mean ± standard deviation or median \[25th-75th percentile\] according to its distribution. The existence of an inflexion point will be summarized as number (percentage) and 95% confidence interval. The airway pressure corresponding to this inflexion point will be summarized as mean ± standard deviation or median \[25th-75th percentile\] according to its distribution.

    Time frame: At inclusion

  3. To assess the airway pressure value of the inflection point on the low-flow deflation pressure-volume curve in patients with an inflexion point on the low-flow deflation pressure-volume curve

    The airway pressure corresponding to the inflexion point on the low-flow deflation pressure-volume curve will be summarized as mean ± standard deviation or median \[25th-75th percentile\] according to its distribution.

    Time frame: At inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Suki B, Barabasi AL, Hantos Z, Petak F, Stanley HE. Avalanches and power-law behaviour in lung inflation. Nature. 1994 Apr 14;368(6472):615-8. doi: 10.1038/368615a0. PubMed 8145846 ↗
  • Chen L, Del Sorbo L, Grieco DL, Shklar O, Junhasavasdikul D, Telias I, Fan E, Brochard L. Airway Closure in Acute Respiratory Distress Syndrome: An Underestimated and Misinterpreted Phenomenon. Am J Respir Crit Care Med. 2018 Jan 1;197(1):132-136. doi: 10.1164/rccm.201702-0388LE. No abstract available. PubMed 28557528 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05224323
Lead sponsor
Poitiers University Hospital
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Mar 1, 2022
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Rémi Coudroy, MD, PhD
Contact
remi.coudroy@chu-poitiers.fr
+ 33 5 49 44 40 07
Céline DELETAGE
Contact
celine.deletage@chu-poitiers.fr
+33 5 49 44 38 54

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion